TrialJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2011

Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.

Melissa L Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.